Literature DB >> 9034775

Comparison of heparin-binding to lactoferrin from human milk and from human granulocytes by means of affinity capillary electrophoresis.

N H Heegaard1, J Brimnes.   

Abstract

Human lactoferrin from two different sources: milk and secondary granules of neutrophil granulocytes, was compared with respect to heparin binding by means of affinity capillary electrophoresis. This method is based on analysis of migration pattern shifts induced by various amounts of ligand present in the electrophoresis buffer. Since lactoferrin is a basic molecule, analyses were performed at pH 8 in a capillary with a neutral hydrophilic coating. However, analyzable peaks were only obtained in the presence of heparin in the electrophoresis buffer. Proportionally to the amount of heparin present, these peaks exhibited shape changes and strong migration shifts. In the ensuing analysis it could be demonstrated that the two lactoferrins had comparable migration shifts and peak shape changes. This indicates that also in this respect the two forms of lactoferrin are identical. Affinity capillary electrophoresis is a convenient and fast method to investigate functional characteristics of low amounts of unmodified biomolecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9034775     DOI: 10.1002/elps.1150171218

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  2 in total

1.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

2.  Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis.

Authors:  L Vasiliauskiene; A Wiik; M Høier-Madsen
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.